Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development Article

Fuse, Marisa A, Dinh, Christine T, Vitte, Jeremie et al. (2019). Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development . NEURO-ONCOLOGY, 21(4), 486-497. 10.1093/neuonc/noz002

Open Access International Collaboration

cited authors

  • Fuse, Marisa A; Dinh, Christine T; Vitte, Jeremie; Kirkpatrick, Joanna; Mindos, Thomas; Plati, Stephani Klingeman; Young, Juan I; Huang, Jie; Carlstedt, Annemarie; Franco, Maria Clara; Brnjos, Konstantin; Nagamoto, Jackson; Petrilli, Alejandra M; Copik, Alicja J; Soulakova, Julia N; Bracho, Olena; Yan, Denise; Mittal, Rahul; Shen, Rulong; Telischi, Fred F; Morrison, Helen; Giovannini, Marco; Liu, Xue-Zhong; Chang, Long-Sheng; Fernandez-Valle, Cristina

sustainable development goals

authors

publication date

  • April 1, 2019

published in

keywords

  • COMBINATION
  • Clinical Neurology
  • GDC-0973
  • Life Sciences & Biomedicine
  • MALIGNANT-TRANSFORMATION
  • MEK inhibitors
  • MTORC1 INHIBITION
  • NF2 transgenic mice
  • Neurosciences & Neurology
  • Oncology
  • PHASE-II
  • PI3K
  • PROGRESSIVE VESTIBULAR SCHWANNOMA
  • SELUMETINIB
  • SUPPRESSES GROWTH
  • Science & Technology
  • TUMORS
  • merlin tumor suppressor
  • methylome
  • patient-derived vestibular schwannomas

Digital Object Identifier (DOI)

publisher

  • OXFORD UNIV PRESS INC

start page

  • 486

end page

  • 497

volume

  • 21

issue

  • 4